OraSure Technologies Inc
Fechado
SetorSaúde
3.06 -1.92
Visão Geral
Variação de preço das ações
24h
Mín
3.05
Máximo
3.09
Rendimento | -2.3M -16M |
|---|---|
Vendas | -322K 27M |
Margem de lucro | -59.946 |
Funcionários | 500 |
EBITDA | -7.8M -19M |
Próximos Ganhos | 4 de ago. de 2026 |
|---|
Capitalização de Mercado | 11M 212M |
|---|---|
Abertura anterior | 4.98 |
Fecho anterior | 3.06 |
Sentimento de Notícias
By Acuity
50%
50%
153 / 347 Ranking em Healthcare
Pontuação Técnica
By Trading Central
Confiança
Strong Bearish Evidence
OraSure Technologies Inc Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Notícias Relacionadas
Comparação entre Pares
Variação de preço
OraSure Technologies Inc Previsão
Sentimento
By Acuity
153 / 347 Ranking em Saúde
Sentimento de Notícias
Neutral
Volatilidade
Abaixo da média
Volume de Notícias (RCV)
Abaixo da média
Informação Financeira
Custos administrativos e de venda
Custos Operacionais
Lucro antes de imposto
Vendas
Custo das vendas
Lucro bruto sobre vendas
Despesa com juros da dívida
EBITDA
Resultado Operacional
$
Sobre OraSure Technologies Inc
OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.
